Assuming sNDA filed at the FDA was BASF, timing would coincide with both Chemport and BASF announcements in December, what excuse would Amarin have for not filing an 8-K in the 4 business day window?
FDA APROVAL of an API supplier is no doubt a must 8-K.
Biobillionair - are you sure exclusivity determination doesn't tie back to the original drug filing for Vascepa - as opposed to the sNDA review acceptance for ANCHOR in 4/2013? If it does tie back to the original review for Vascepa MARINE then that pre-dates the 11/2012 initiation. BTW - I HOPE you're correct in a big way! Thx.